Welcome to our dedicated page for Aspire Biopharma Holdings news (Ticker: ASBP), a resource for investors and traders seeking the latest updates and insights on Aspire Biopharma Holdings stock.
Aspire Biopharma Holdings, Inc. develops sublingual delivery technology designed to deliver drugs and other bioactive substances through rapid absorption under the tongue. Company news commonly covers its drug-delivery platform, applications across active pharmaceutical ingredients, therapeutics, nutraceuticals and supplements, and clinical or regulatory disclosures tied to its development activities.
Updates also include the company’s wholly owned Buzz Bomb Caffeine Company, which markets BUZZ BOMB™ caffeine in single-serving dry powder stick packs for sublingual use. Recurring corporate developments include retail distribution and sales agreements, operating and financial results, shareholder voting matters, governance updates, Nasdaq listing compliance and capital-structure actions such as reverse stock split approvals.
Aspire Biopharma (NASDAQ:ASBP) announced on February 19, 2026 that its subsidiary BUZZ BOMB™ Caffeine Company named ChicExecs as its public relations agency of record as it pursues brand expansion, product innovation, and a comprehensive brand refresh.
ChicExecs will lead media relations, events, strategic partnerships, and PR campaigns to position BUZZ BOMB™—a 50mg sublingual caffeine powder in single-serving stick packs—across food, beverage, fitness, and lifestyle channels.
Aspire Biopharma (NASDAQ:ASBP) filed a provisional patent application for a proprietary sublingual powder formulation of meclizine on February 17, 2026. The formulation targets rapid-onset relief, aiming to cut typical oral onset from about 60 minutes to minutes and to support a 505(b)(2) regulatory path.
The company cites ~4.09 million U.S. prescriptions in 2023 and a $450M global meclizine market, projecting growth to $650M by 2032.
Aspire Biopharma (Nasdaq: ASBP) appointed Phillip Balatsos to its Board of Directors, effective February 6, 2026, following the planned departures of Suren Ajjarapu and Donald G. Fell.
Balatsos brings 25+ years of capital markets and entrepreneurial experience and will serve on the Audit and Compensation Committees, supporting Aspire's strategy to reformulate established drugs using its patent-pending sublingual delivery platform.
Aspire Biopharma (Nasdaq:ASBP) filed a provisional USPTO patent application on February 12, 2026 for a sublingual powder formulation of ondansetron, aimed at rapid relief of chemotherapy-, radiation- and surgery-induced nausea.
The company highlights potential near-instant absorption versus 30-minute oral tablets, plans to pursue an FDA 505(b)(2) pathway, and cites >12.5 million U.S. prescriptions and a ~$1.4B global market (2023).
Aspire Biopharma (Nasdaq:ASBP) entered a securities purchase agreement to sell up to 26,250 Series A convertible preferred shares at $800 per share for aggregate gross proceeds of up to $21.0 million. An initial closing on February 6, 2026 issued 13,750 shares for $11.0 million.
Proceeds will repay legacy indebtedness, support operations and strategic initiatives, and are expected to help the company regain compliance with Nasdaq stockholders' equity requirements. A second closing is subject to customary conditions. RBW Capital Partners acted as sole placement agent.
Aspire Biopharma (Nasdaq: ASBP) regained compliance with Nasdaq Listing Rule 5550(a)(2) after achieving a closing bid of at least $1.00 per share for 10 consecutive business days, and Nasdaq confirmed the matter is closed on February 10, 2026.
The company remains subject to an extension to evidence compliance with the $2.5 million stockholders' equity requirement and says it has made progress on strategic plans for 2026 with additional details to follow.
Aspire Biopharma (NASDAQ:ASBP) subsidiary Buzz Bomb Caffeine Company will showcase its flagship BUZZ BOMB™ sublingual caffeine at The Sports & Active Nutrition Summit USA in San Diego on February 18-20, 2026. The product delivers a rapid 50mg caffeine dose via single-serving stick packs in four flavors and features new branding and a redesigned mobile website for direct purchase.
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company signed a strategic brand management and distribution agreement with Blue Shark Beverages, effective February 1, 2026, to expand BUZZ BOMB™ retail placement across Southern California.
The rollout debuts in Palm Springs and Coachella Valley, then phases into Los Angeles and San Diego, targeting resorts, hotels, casinos, festival channels and broader retail outlets.
Aspire Biopharma (Nasdaq:ASBP) has signed an agreement with Microsize to support development of a 162 mg sublingual aspirin powder for emergency treatment of suspected acute myocardial infarction. The collaboration targets optimized drug product for an upcoming clinical trial and a planned Section 505(b)(2) NDA submission near end of 2026.
The clinical study will compare serum thromboxane B2 inhibition in 32 healthy volunteers versus two chewed 81 mg aspirin tablets; Microsize will provide cGMP micronization and particle‑engineering services to advance formulation and commercial manufacturing readiness.
Aspire Biopharma (Nasdaq:ASBP) announced filing a provisional patent application with the USPTO for the first-ever sublingual powder formulation of clopidogrel.
The filing covers a sublingual delivery system intended to improve clopidogrel pharmacokinetics by enabling absorption under the tongue, potentially increasing bioavailability and reducing or eliminating gastric irritation associated with oral tablets. Aspire plans to pursue commercialization via the FDA 505(b)(2) pathway and positions this program alongside its other reformulation efforts, including an investigational acetylsalicylic acid 162 mg sublingual powder (OTASA) intended for emergency myocardial infarction treatment.